Stoke Therapeutics (STOK) Accumulated Expenses (2018 - 2026)

Stoke Therapeutics has reported Accumulated Expenses for 9 years, with the latest figure at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 87.36% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 million (down 87.36% YoY), and the FY2025 full-year result was $41.0 million, up 121.01% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $3.1 million, down from $41.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $41.0 million in Q4 2025, with the low at $1.5 million in Q1 2023.
• Average Accumulated Expenses over 5 years is $11.8 million, with a median of $7.2 million recorded in 2025.
• Year-over-year, Accumulated Expenses surged 929.47% in 2022 and tumbled 87.36% in 2026.
• Tracing STOK's Accumulated Expenses over 5 years: stood at $5.8 million in 2022, then retreated by 2.49% to $5.6 million in 2023, then jumped by 230.9% to $18.6 million in 2024, then jumped by 121.01% to $41.0 million in 2025, then sank by 92.5% to $3.1 million in 2026.
• The last three Accumulated Expenses figures came in at $3.1 million (Q1 2026), $41.0 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.

Peer Comparison